Replimune Group Inc (REPL)

$8.88 +0.26 (3.02%)
Market Cap 733.25M
Revenue (ttm) 0.00
Net Income (ttm) -247.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.23
Volume 1,972,900
Avg Vol 8,985,290
Day's Range N/A - N/A
Shares Out 82.57M
Stochastic %K 24%
Beta 0.91
Analysts Hold
Price Target $4.67

Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express a...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 222 9600
Address:
500 Unicorn Park Drive, Suite 303, Woburn, United States
Tom2772
Tom2772 Jun. 15 at 5:29 AM
$OTLK $REPL $IBRX Right now it's all about the FDA decision After that, investors may start asking a different question. What is an FDA-approved ophthalmology asset with approvals in the EU and UK actually worth? That's when strategic interest becomes a much more realistic discussion. The pieces keep falling into place. 🧩 The investment case keeps getting stronger. 💪
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 14 at 3:52 PM
$REPL Replimune Group Inc. (NASDAQ: REPL) is back on biotech investors’ radar after a painful FDA setback and a possible second shot for RP1. Is this cancer biotech stock a risky trap or a turnaround story worth watching? https://biotechhealthx.com/biotech-news/could-replimune-repl-be-a-smart-long-term-bet-in-oncology-innovation/
3 · Reply
History101
History101 Jun. 13 at 12:34 AM
$REPL stock price action week of Mon, June 8, 2026:
0 · Reply
History101
History101 Jun. 12 at 8:05 PM
$REPL good call, REPL closed at $8.88 today, up 3%
1 · Reply
Tom2772
Tom2772 Jun. 12 at 7:36 PM
$OTLK $REPL $IBRX THIS IS THE WAY
1 · Reply
beachsidefreddy
beachsidefreddy Jun. 12 at 4:02 PM
$REPL “DOWN GOES FRAZIER….DOWN GOES FRAZIER!!!”
0 · Reply
Mmohammad77
Mmohammad77 Jun. 12 at 1:34 PM
$CHR $OTLK $REPL $SDOT $HSDT CHR is the next one
0 · Reply
beachsidefreddy
beachsidefreddy Jun. 12 at 1:01 PM
$REPL STARLINK MAY GO UP REPL DOWN
0 · Reply
Dorps332
Dorps332 Jun. 12 at 12:51 PM
$REPL will they actually do their earnings today?
0 · Reply
Tom2772
Tom2772 Jun. 12 at 11:44 AM
$OTLK $IBRX $REPL Absolutely right! 🚀🔥
0 · Reply
Latest News on REPL
Replimune Group trading resumes

2026-06-01T16:21:43.000Z - 13 days ago

Replimune Group trading resumes

Replimune Group trading halted, volatility trading pause

2026-06-01T13:36:30.000Z - 13 days ago

Replimune Group trading halted, volatility trading pause

Replimune price target raised to $6 from $2 at Wedbush

2026-06-01T13:07:02.000Z - 13 days ago

Replimune price target raised to $6 from $2 at Wedbush

Replimune presents final first-in-human data for RP2 alone, with nivolumab

2026-05-31T21:15:05.000Z - 14 days ago

Replimune presents final first-in-human data for RP2 alone, with nivolumab

Replimune presents 3-year overall survival data from IGNYTE trial

2026-05-31T20:35:04.000Z - 14 days ago

Replimune presents 3-year overall survival data from IGNYTE trial

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 31, 2026, 8:00 AM EDT - 14 days ago

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 30, 2026, 8:00 AM EDT - 15 days ago

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

How Replimune's drug got a third chance after the White House intervened

May 29, 2026, 9:53 PM EDT - 16 days ago

How Replimune's drug got a third chance after the White House intervened

Replimune upgraded to Neutral at JPMorgan with RP1 ‘back on the table’

2026-05-29T17:31:42.000Z - 16 days ago

Replimune upgraded to Neutral at JPMorgan with RP1 ‘back on the table’

Replimune upgraded to Neutral from Underweight at JPMorgan

2026-05-29T17:28:48.000Z - 16 days ago

Replimune upgraded to Neutral from Underweight at JPMorgan

Why Penny Stock Replimune (REPL) Nearly Doubled Today

2026-05-29T14:55:13.000Z - 16 days ago

Why Penny Stock Replimune (REPL) Nearly Doubled Today

BMY

Replimune to resubmit RP1 BLA following communications with FDA

2026-05-29T13:09:45.000Z - 16 days ago

Replimune to resubmit RP1 BLA following communications with FDA

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

May 29, 2026, 8:51 AM EDT - 16 days ago

Replimune to resubmit twice-rejected drug for approval after FDA shakeup

Replimune reaches agreement with US FDA to resubmit melanoma drug application

May 29, 2026, 8:07 AM EDT - 16 days ago

Replimune reaches agreement with US FDA to resubmit melanoma drug application

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

May 29, 2026, 8:00 AM EDT - 16 days ago

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

Replimune Gets Third Try at FDA Approval After Makary Departure

May 29, 2026, 7:30 AM EDT - 16 days ago

Replimune Gets Third Try at FDA Approval After Makary Departure

Replimune jumps on news FDA chief behind RP1 rejection may be removed

2026-05-08T18:59:46.000Z - 5 weeks ago

Replimune jumps on news FDA chief behind RP1 rejection may be removed

FDA Commissioner Makary defends agency's decision on Replimune's drug

May 5, 2026, 10:58 AM EDT - 5 weeks ago

FDA Commissioner Makary defends agency's decision on Replimune's drug

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Apr 22, 2026, 12:56 PM EDT - 7 weeks ago

US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Replimune rises after Wall Street Journal editorial defending RP1

2026-04-22T15:00:52.000Z - 7 weeks ago

Replimune rises after Wall Street Journal editorial defending RP1

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'

Apr 13, 2026, 11:46 AM EDT - 2 months ago

Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

Apr 10, 2026, 5:02 PM EDT - 2 months ago

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

US FDA declines to approve Replimune's drug for advanced skin cancer

Apr 10, 2026, 11:24 AM EDT - 2 months ago

US FDA declines to approve Replimune's drug for advanced skin cancer

Replimune Group Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 2:20 PM EDT - 3 months ago

Replimune Group Transcript: Leerink Global Healthcare Conference 2026

Replimune to Present at Two Upcoming Investor Conferences

Mar 2, 2026, 8:00 AM EST - 3 months ago

Replimune to Present at Two Upcoming Investor Conferences

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Feb 3, 2026, 8:00 AM EST - 4 months ago

Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

Replimune Group Quarterly report: Q3 2026

Feb 3, 2026, 8:00 AM EST - 4 months ago

Replimune Group Quarterly report: Q3 2026

Replimune Group Earnings release: Q3 2026

Feb 3, 2026, 8:00 AM EST - 4 months ago

Replimune Group Earnings release: Q3 2026

Replimune Group Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 5 months ago

Replimune Group Transcript: 44th Annual J.P. Morgan Healthcare Conference

Replimune Group Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 4:30 PM EST - 5 months ago

Replimune Group Slides: 44th Annual J.P. Morgan Healthcare Conference

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 6 months ago

Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Nov 7, 2025, 4:45 PM EST - 7 months ago

Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)

Replimune Group Earnings release: Q2 2026

Nov 6, 2025, 8:30 AM EST - 7 months ago

Replimune Group Earnings release: Q2 2026

Replimune Group Quarterly report: Q2 2026

Nov 6, 2025, 8:30 AM EST - 7 months ago

Replimune Group Quarterly report: Q2 2026

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Nov 6, 2025, 8:00 AM EST - 7 months ago

Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

Replimune Group Registration statement: Registration Filing

Nov 6, 2025, 7:00 AM EST - 7 months ago

Replimune Group Registration statement: Registration Filing

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Oct 20, 2025, 7:00 AM EDT - 8 months ago

Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Oct 19, 2025, 8:00 AM EDT - 8 months ago

Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025

Replimune Provides Update Following Type A Meeting with FDA

Sep 18, 2025, 9:15 AM EDT - 9 months ago

Replimune Provides Update Following Type A Meeting with FDA

Replimune Group Transcript: AGM 2025

Sep 3, 2025, 11:30 AM EDT - 10 months ago

Replimune Group Transcript: AGM 2025

Replimune Announces Type A Meeting Scheduled with FDA

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Replimune Announces Type A Meeting Scheduled with FDA

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

Replimune Group Earnings release: Q1 2026

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Replimune Group Earnings release: Q1 2026

Replimune Group Quarterly report: Q1 2026

Aug 7, 2025, 7:00 AM EDT - 11 months ago

Replimune Group Quarterly report: Q1 2026

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

Jul 30, 2025, 8:36 AM EDT - 11 months ago

REPL INVESTORS: Replimune Group, Inc. (NASDAQ:REPL) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Jul 28, 2025, 8:36 AM EDT - 11 months ago

REPL LAWSUIT: Replimune Group, Inc. Sued for Fraud after FDA Response Letter – Contact BFA Law by September 22 Court Deadline (NASDAQ:REPL)

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jul 25, 2025, 5:04 PM EDT - 11 months ago

Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm

Tom2772
Tom2772 Jun. 15 at 5:29 AM
$OTLK $REPL $IBRX Right now it's all about the FDA decision After that, investors may start asking a different question. What is an FDA-approved ophthalmology asset with approvals in the EU and UK actually worth? That's when strategic interest becomes a much more realistic discussion. The pieces keep falling into place. 🧩 The investment case keeps getting stronger. 💪
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 14 at 3:52 PM
$REPL Replimune Group Inc. (NASDAQ: REPL) is back on biotech investors’ radar after a painful FDA setback and a possible second shot for RP1. Is this cancer biotech stock a risky trap or a turnaround story worth watching? https://biotechhealthx.com/biotech-news/could-replimune-repl-be-a-smart-long-term-bet-in-oncology-innovation/
3 · Reply
History101
History101 Jun. 13 at 12:34 AM
$REPL stock price action week of Mon, June 8, 2026:
0 · Reply
History101
History101 Jun. 12 at 8:05 PM
$REPL good call, REPL closed at $8.88 today, up 3%
1 · Reply
Tom2772
Tom2772 Jun. 12 at 7:36 PM
$OTLK $REPL $IBRX THIS IS THE WAY
1 · Reply
beachsidefreddy
beachsidefreddy Jun. 12 at 4:02 PM
$REPL “DOWN GOES FRAZIER….DOWN GOES FRAZIER!!!”
0 · Reply
Mmohammad77
Mmohammad77 Jun. 12 at 1:34 PM
$CHR $OTLK $REPL $SDOT $HSDT CHR is the next one
0 · Reply
beachsidefreddy
beachsidefreddy Jun. 12 at 1:01 PM
$REPL STARLINK MAY GO UP REPL DOWN
0 · Reply
Dorps332
Dorps332 Jun. 12 at 12:51 PM
$REPL will they actually do their earnings today?
0 · Reply
Tom2772
Tom2772 Jun. 12 at 11:44 AM
$OTLK $IBRX $REPL Absolutely right! 🚀🔥
0 · Reply
Wagner2000
Wagner2000 Jun. 12 at 10:12 AM
$REPL should be a good day!
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 12 at 9:48 AM
$EWTX $IOVA $NRIX $KALV $REPL Small-cap biotech stocks are heating up as investors hunt for FDA catalysts, rare disease breakthroughs, cancer treatments, and Big Pharma buyout potential. These 10 biotech names could be among the most interesting stocks to watch now. https://biotechhealthx.com/biotech-news/top-10-small-cap-biotech-stocks-that-could-surge-100/
1 · Reply
bilocelhi
bilocelhi Jun. 12 at 8:49 AM
$REPL def a buy!
0 · Reply
Tom2772
Tom2772 Jun. 12 at 7:12 AM
$OTLK $REGN $REPL FDA confirmed "Substantial Evidence of Effectiveness." BLA resubmitted. EU ✅ UK ✅ Class 1 review (~60 days) ⏳ Final FDA decision ahead. The path to US approval has never been clearer. The story has fundamentally changed for $OTLK 🚀🔥📈
1 · Reply
Mmohammad77
Mmohammad77 Jun. 11 at 11:03 PM
$CHR $VCIG $WOLF $AEHL $REPL CHR will be huge soon
0 · Reply
goldengatesings2
goldengatesings2 Jun. 11 at 9:07 PM
$REPL god what a useless board. Can’t stop yawning. Is there any other place which has good discusssions of REPL?
0 · Reply
jtsxlr
jtsxlr Jun. 11 at 5:11 PM
$MSTR Looking at the option chain, There's more weekly 115 puts than calls, my hunch is they will not pay those puts, therefore this closes above 115 tomorrow. Just a guess while having the oversold RSI on my side. lol $UEC , $VRRM , $REPL , $ZENA
1 · Reply
jtsxlr
jtsxlr Jun. 11 at 3:26 PM
$VRRM Vroom Vroom !!! $REPL , $ZENA , $MSTR , $TSLA
0 · Reply
WelshDragon75
WelshDragon75 Jun. 11 at 12:35 PM
$REPL so so many predictions of doom and gloom. And yet still above $8 and holding up. Follow the noise, and go opposite!
1 · Reply
beachsidefreddy
beachsidefreddy Jun. 11 at 12:13 PM
$REPL "THE EMPEROR HAS NO CLOTHES" NOW ALL THE BS HAMBURGER FLIPPERS OUT OF STOCK ITS LEFT ALONE WITH NO FDA, NO MONEY AND NO STAFF. ITS A SAD SCAM.
0 · Reply
PatienceToWin
PatienceToWin Jun. 11 at 4:38 AM
$REPL I "The resubmission, described as imminent," Massachusetts-based Replimune Group (Nasdaq: REPL) has announced plans to resubmit a Biologics License Application (BLA) to the US FDA for Rp1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 based therapy. The resubmission, described as imminent, follows what the company characterized as productive dialogue with the agency and represents a renewed attempt to secure approval for an oncolytic immunotherapy in a patient population with limited post-checkpoint options. When will be the Resubmission?
1 · Reply
AllAboutTheBread
AllAboutTheBread Jun. 11 at 1:13 AM
$REPL looks like 7.70 or lower is on horizon tomorrow. good day to be a short.
1 · Reply